menu
    • menu

    Company profile for Incyte Corporation

    NEW Drugs in Dev: 68
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Incyte's vision is to become a leading biopharmaceutical company by building a proprietary pipeline of novel small molecule drugs for serious unmet medical needs primarily in the area of oncology. The field of oncology is evolving rapidly and transforming how cancer is and will be treated. With a growing pipeline that includes innovative compounds in three major oncology areas -- onco-inflammation, immuno-oncology and targeted...
    Incyte's vision is to become a leading biopharmaceutical company by building a proprietary pipeline of novel small molecule drugs for serious unmet medical needs primarily in the area of oncology. The field of oncology is evolving rapidly and transforming how cancer is and will be treated. With a growing pipeline that includes innovative compounds in three major oncology areas -- onco-inflammation, immuno-oncology and targeted therapies -- we believe Incyte is at the center of this transformation in cancer care.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Incyte CorporationUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1801 Augustine Cut-off Wilmington, DE 19803
    Telephone
    Telephone
    +1 1.855.446.2983
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.incyte.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Warns Three Firms For GMP Violations, Cites Incyte
    FDA Warns Three Firms For GMP Violations, Cites Incyte

    30 Apr 2026

    // RAPS

    https://www.raps.org/resource/fda-warns-three-firms-for-gmp-violations-cites-incyte-for-misleading-claims.html

    RAPS
    30 Apr 2026
    Share Share
    Incyte Claims Double Phase 3 Wins in Vitiligo, Plans NDA Filing
    Incyte Claims Double Phase 3 Wins in Vitiligo, Plans NDA Filing

    29 Apr 2026

    // ENDPOINTS

    https://endpoints.news/incyte-claims-double-phase-3-win-in-vitiligo-will-file-for-approval/

    ENDPOINTS
    29 Apr 2026
    Share Share
    Incyte Exceeds Q1 Estimates With Strong Cancer Drug Demand
    Incyte Exceeds Q1 Estimates With Strong Cancer Drug Demand

    28 Apr 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/incyte-beats-first-quarter-estimates-strong-demand-cancer-drugs-2026-04-28/

    REUTERS
    28 Apr 2026
    Share Share
    Incyte Appoints Suketu (Suky) Upadhyay As Chief Financial Officer
    Incyte Appoints Suketu (Suky) Upadhyay As Chief Financial Officer

    28 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-28/incyte-appoints-suketu-suky-upadhyay-as-chief-financial-officer

    PHARMIWEB
    28 Apr 2026
    Share Share
    Incyte to Report First Quarter Financial Results
    Incyte to Report First Quarter Financial Results

    09 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260409506560/en/Incyte-to-Report-First-Quarter-Financial-Results

    BUSINESSWIRE
    09 Apr 2026
    Share Share
    Adagene & Incyte to Trial Muzastotug + TGFßR2xPD-1 in CRC
    Adagene & Incyte to Trial Muzastotug + TGFßR2xPD-1 in CRC

    02 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/02/3267231/0/en/Adagene-Announces-Clinical-Collaboration-with-Incyte-to-Evaluate-Muzastotug-ADG126-in-Combination-with-Incyte-s-TGF%C3%9FR2xPD-1-Bispecific-Antibody-INCA33890-in-Patients-with-Microsate.html

    GLOBENEWSWIRE
    02 Apr 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search